文献速递白血病

法国停用伊马替尼(STIM1)研究在慢性髓性白血病患者中的长期随访

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
PubMed 文献 · J Clin Oncol · 2016-10-31

STIM1研究前瞻性停用100例持续至少2年未检出微小残留病(UMRD)的慢性髓性白血病(CML)患者伊马替尼,中位分子学随访77个月;61例在中位2.5个月丢失UMRD,6个月无分子学复发生存率43%,60个月38%,无CML进展,Sokal风险评分和伊马替尼治疗时长与分子学复发概率显著相关。

要点

  • 持续至少2年UMRD的CML患者停用伊马替尼后,60个月无分子学复发生存率为38%(95%CI 29%至47%)。
  • 61例在中位2.5个月丢失UMRD,57例重启治疗,55例中位4个月再次达到UMRD,无CML进展。
  • Sokal风险评分和伊马替尼治疗时长与分子学复发概率显著相关。

核心结论

  • 停用伊马替尼后中位随访超过6年,STIM1研究显示持续深度分子学缓解的患者可安全停用伊马替尼,无晚期分子学复发。

研究设计与样本

  • STIM1研究为前瞻性停用伊马替尼研究,纳入100例UMRD持续至少2年的CML患者。

主要发现

  • 停用治疗后中位分子学随访77个月(范围9至95个月)。
  • 61例在中位2.5个月(范围1至22个月)丢失UMRD,1例在10个月时带UMRD死亡。
  • 6个月无分子学复发生存率43%(95%CI 33%至52%),60个月为38%(95%CI 29%至47%)。
  • 61例分子学复发中57例重启治疗,55例在中位4个月(范围1至16个月)再次达到UMRD。
  • 无患者出现CML进展;Sokal风险评分和伊马替尼治疗时长与分子学复发概率显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. We report the final results of the Stop Imatinib (STIM1) study with a long follow-up. Patients and Methods IM was prospectively discontinued in 100 patients with CML with UMRD sustained for at least 2 years. Molecular recurrence (MR) was defined as positivity of BCR-ABL transcript in a quantitative reverse transcriptase polymerase chain reaction assay confirmed by a second analysis point that indicated an increase of one log in relation to the first analysis point at two successive assessments or loss of major molecular response at one point. Results The median molecular follow-up after treatment discontinuation was 77 months (range, 9 to 95 months). Sixty-one patients lost UMRD after a median of 2.5 months (range, 1 to 22 months), and one patient died with UMRD at 10 months. Molecular recurrence-free survival was 43% (95% CI, 33% to 52%) at 6 months and 38% (95% CI, 29% to 47%) at 60 months. Treatment was restarted in 57 of 61 patients with MR, and 55 patients achieved a second UMRD with a median time of 4 months (range, 1 to 16 months). None of the patients experienced a CML progression. Analyses of the characteristics of the study population identified that the Sokal risk score and duration of IM treatment were significantly associated with the probability of MR. Conclusion With a median follow-up of more than 6 years after treatment discontinuation, the STIM1 study demonstrates that IM can safely be discontinued in patients with a sustained deep molecular response with no late MR.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Etienne G, Guilhot J, Rea D, et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2016. PMID: 28095277. doi:10.1200/JCO.2016.68.2914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。